Clinical Trials Browser

Phase 3 × INDUSTRY × Prednisolone × Clear all

NCT06717347 2026-05-29

MK-2140-010

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06925737 2026-05-29

MK-2400-001

Phase 3 Recruiting

Prostatic Neoplasms

NCT06911502 2026-05-20

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Phase 3 Recruiting

Lymphoma, Follicular

NCT06091254 2026-05-19

OLYMPIA-1

Phase 3 Recruiting

Lymphoma, Follicular

NCT06952803 2026-05-19

EvoPAR-PR02

Phase 3 Recruiting

Prostatic Neoplasms

NCT06091865 2026-05-15

OLYMPIA-3

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06764485 2026-05-06

rechARge

Phase 3 Recruiting

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT07365995 2026-05-05

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Phase 3 Recruiting

Metastatic Castration-resistant Prostate Cancer

NCT05888493 2026-04-17

LEDA

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT05288166 2025-06-27

CYCLONE 3

Phase 3 Active not recruiting

925 enrolled 12 charts

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

NCT03072238 2025-06-06

IPATential150

Phase 3 Completed

1,101 enrolled 35 charts

Prostatic Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

Phase 3 Completed

793 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT02288247 2025-04-08

PRESIDE

Phase 3 Completed

688 enrolled 13 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT02043678 2025-02-19

ERA 223

Phase 3 Completed

806 enrolled 32 charts

Prostatic Neoplasms

NCT01539083 2025-02-04

VCAT

Phase 3 Completed

256 enrolled 13 charts

Multiple Myeloma

NCT02162771 2020-01-29

rituximab

Phase 3 Completed

140 enrolled 9 charts

Lymphoma, Follicular

NCT01200758 2018-11-27

A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma

Phase 3 Completed

410 enrolled 33 charts

Lymphoma, Non-Hodgkin

NCT01724021 2018-01-23

A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a

Phase 3 Completed

743 enrolled 16 charts

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00562965 2018-01-09

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Phase 3 Terminated

29 enrolled 14 charts

Lymphoma, Follicular

NCT01308580 2017-04-17

PROSELICA

Phase 3 Completed

1,200 enrolled 25 charts

Prostatic Neoplasms

NCT00519285 2016-07-22

VENICE

Phase 3 Completed

1,224 enrolled 21 charts

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00638690 2014-04-30

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Phase 3 Completed

1,195 enrolled 12 charts

Prostatic Neoplasms

NCT00822809 2012-10-03

CASIMAS

Phase 3 Completed

Carcinoma, Neoplasms